Page last updated: 2024-08-21

pyrazines and Breast Cancer

pyrazines has been researched along with Breast Cancer in 114 studies

Research

Studies (114)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.88)	18.2507
2000's	37 (32.46)	29.6817
2010's	69 (60.53)	24.3611
2020's	7 (6.14)	2.80

Authors

Authors	Studies
Feng, Y; Fu, X; Li, Z; Lin, F; Lv, J; Mao, Q; Mou, Y; Wang, S; Yang, Y; Zhang, B; Zhang, L; Zhang, P; Zhao, J	1
Kumar, J; Kusanur, R; Niranjan, V; Philip, S; R, V; Uttarkar, A	1
Chen, H; Fang, J; Jiang, S; Ruan, Q; Sun, J; Yang, X; Zhang, M; Zhang, Y; Zhou, F; Zhou, W; Zhu, T	1
Alexi, X; Boven, E; Kruger, DT; Linn, SC; Opdam, M; Sanders, J; Schuurman, K; van der Noort, V; Voorwerk, L; Zwart, W	1
Bajzikova, M; Boukalova, S; Coelho, A; Davidova, E; Ditzel, HJ; Hubackova, S; Kovarova, J; Neuzil, J; Rohlena, J; Terp, MG	1
Andrews, C; Maze, D; Murphy, T; Sibai, H	1
Chen-Yang, Z; Hui, MA; Li-Chun, C; Ming-Kun, S; Qing, F; Ren Bao Li Gao, A; Xiang-Yang, L; Zhen-Long, YU	1
Kim, SB; Nishihara, R; Paulmurugan, R; Suzuki, K	1
Morimoto-Kamata, R; Yui, S	1
Cui, G; Deng, H; Lee, SM; Lu, Y; Shan, L; Zhang, Y; Zhou, H	1
Afjei, R; Citterio, D; Hiruta, Y; Iwasawa, N; Kim, SB; Nakajima, T; Natarajan, A; Nishihara, R; Nishiyama, S; Paulmurugan, R; Sato, M; Suzuki, K; Yamamoto, E	1
Bruni-Cardoso, A; Fiore, APZP; Gomes, LR; Kinker, GS; Martins, DJ; Menck, CFM; Rocha, CRR	1
Cabañas, C; Cardeñes, B; López-Martín, S; Morales, S; Toribio, V; Yáñez-Mó, M	1
Abu-Odeh, R; Al-Qawasmeh, RA; Al-Tel, TH; Chouaib, S; El-Awady, R; Saber-Ayad, M; Semreen, MH; Voelter, W	1
Altıkat, S; Boyaci, I; Cavga, FZ; Irmak, R; Kocacan, SA; Yerlikaya, A	1
Che, XF; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Yokoyama, T	1
Erdoğan, E; Genç, O; Savran, B; Yerlikaya, A	1
Aoyama, K; Asano, M; Dougan, DR; Hamada, T; Hashimoto, K; Ishikawa, T; Mol, CD; Morishita, N; Saito, B; Shiokawa, Z; Sumi, H; Yabuki, M; Yoshida, S; Yoshimatsu, M	1
Khan, S; Li, WH; Sun, SR; Tang, Z; Wan, JN; Wang, CH; Yao, F; Zhang, YM; Zhu, S	1
Condelli, V; Esposito, F; Landriscina, M; Lettini, G; Maddalena, F; Matassa, DS; Sisinni, L	1
Abramova, EB; Astakhova, TM; Bogomyagkova, YV; Choinzonov, EL; Erokhov, PA; Kondakova, IV; Kuznetsov, NA; Lyupina, YV; Plekhanova, AS; Rodoman, GV; Sharova, NP; Shashova, EE; Slonimskaya, EM; Sumedi, IR	1
Iyengar, R; Luker, GD; Luker, KE; Moudgil, P; Nyati, S; Rehemtulla, A; Stacer, AC	1
Borzym-Kluczyk, M; Cechowska-Pasko, M; Krętowski, R	1
Anderson, KC; Hide, M; Hideshima, H; Hideshima, T; Ikeda, H; Iwasaki, A; Yoshida, Y	1
Chen, JH; Guo, XL; Liu, XY; Wang, HY; Zhang, P; Zheng, BB	1
Chen, J; Guo, X; Liu, X; Wang, H; Wang, W	1
Bielawska, A; Bielawski, K; Czarnomysy, R; Gornowicz, A; Kałuża, Z; Lepiarczyk, M	1
Acılan, C; Baykal, AT; Boyacı, I; Okur, E; Ulukaya, E; Yerlikaya, A	1
Amin, HM; Angelo, LS; Falchook, GS; Hess, K; Hong, D; Howard, AN; Huang, M; Jackson, EF; Janku, F; Kurzrock, R; Lawhorn, KN; Naing, A; Ng, CS; Parkhurst, KL; Tannir, NM; Vishwamitra, D; Wheler, JJ	1
Chang, HY; Chen, NN; Huang, HC; Huang, TC; Juan, HF	1
Ahmed, M; Goldberg, SN; Kumar, G; Levchenko, T; Moussa, M; Sawant, RR; Torchilin, V	1
Bouwman, P; Greco, D; Gu, Y; Jonkers, J; Kuznetsov, SG; Saarela, J; Yadav, B	1
Hengstler, JG; Schad, A; Schmidt, M; Sleeman, JP; Thaler, S; Thiede, G	1
Chirgwin, JM; Suvannasankha, A	1
Beissbarth, T; Cormet-Boyaka, E; Dobbelstein, M; Edmunds, S; Gaedcke, J; Ghadimi, M; Krüger, E; Levine, AJ; Markert, E; Moll, UM; Schulz, R; Zhang, X	1
Abdel-Fatah, TM; Aleskandarany, MA; Alsubhi, N; Arora, A; Chan, SY; Curtin, NJ; Doherty, R; Ellis, IO; Green, AR; Madhusudan, S; Martin, SG; Middleton, F; Moseley, PM; Rakha, EA; Stephens, P	1
Ahmed, Y; Chen, H; Hu, L; Li, D; Li, Z; Negi, H; Wu, Z; Zheng, Y; Zhu, Q	1
Chan, JY; Cui, G; Di, L; Lee, SM; Li, C; Shan, L; Wang, L; Wang, Y; Xu, C; Zhang, Q; Zhang, X	1
Deng, O; Du, Z; Gao, J; Gorityala, S; Lai, J; Ma, Z; Susana, G; Xiong, X; Xu, Y; Yan, C; Yang, S; Zhang, J; Zhang, Y	1
Fogarty, FM; Kennedy, RD; Lyons, A; McCabe, N; O'Connor, R; O'Flanagan, CH; O'Shea, S	1
Cho, BR; Choi, JW; Han, MS; Hong, ST; Kang, DE; Lim, CS; Paik, KC	1
Argyros, O; Christoforidis, S; Kouvari, E; Lougiakis, N; Marakos, P; Papafotika, A; Pouli, N; Psycharis, V; Raptopoulou, CP; Tamvakopoulos, C	1
Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L	1
Erin, N; Yerlikaya, A	1
Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C	1
Ames, E; Hallett, WH; Murphy, WJ	1
Cao, X; Garofalo, A; Grande, F; Louie, S; Neamati, N; Oshima, T; Yamada, R	1
Bottini, A; Generali, D; Harris, AL; Mellor, HR; Milani, M; Pike, L; Rzymski, T	1
Gupta, M; Luker, G; Luker, K	1
Agyin, JK; Nair, HB; Roy, SS; Santhamma, B; Tekmal, RR	1
Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG	1
Alarid, ET; Casa, AJ; Ellison-Zelski, SJ; Lee, AV; Powers, GL	1
Dou, QP; Lonardo, F; Pass, HI; Puliyappadamba, VT; Rishi, AK; Ruckdeschel, JC; Sharma, S; Tarca, A; Wali, A; Wang, Y; Yang, H	1
Barrett, JR; Bhalla, KN; Erickson, B; Ganapathy, V; Gopal, E; Hill, WD; Jackson, WH; Periyasamy-Thandavan, S; Raney, L; Samaddar, JS; Schoenlein, PV	1
Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y	1
Benz, CC; Gibson, BW; Held, JM; Marx, C	1
Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K	1
Ayers, DC; Barthel, TK; Bouxsein, ML; Cheng, D; Hussain, S; Jones, MD; Lian, JB; Liu, JC; Lovria, E; Mukherjee, S; Mulay, S; Schoonmaker, JA; Stein, GS	1
Bernard, PS; Carey, LA; Chiu, WK; Collichio, FA; Dees, EC; Irvin, WJ; Ivanova, A; Orlowski, RZ; Perou, C; Stijleman, IJ	1
Aguirre-Ghiso, J; Bahadur, U; Germain, D; Ishii, Y; Papa, L; Shioda, T; Waxman, S; Yue, Z	1
Amm, HM; Buchsbaum, DJ; Kuo, H; Li, Y; Steg, AD; Zhou, T	1
Liu, X; Liu, Y; Zhang, JH; Zhang, Y; Zuo, T	1
Oh, A; Yee, D; Zeng, X; Zhang, H; Zhang, Y	1
Arshad Siddiqui, M; Belanger, DB; Bracken, JB; Curran, PJ; Malkowski, M; Miao, H; Shipps, GW; Wang, Y; Zeng, H	1
Begus-Nahrmann, Y; Beissbarth, T; Eick, D; Gorsler, T; Hennion, M; Hintermair, C; Hsu, C; Johnsen, SA; Kramer, F; Kremmer, E; Prenzel, T; Simons, M	1
Arteaga, CL; Balko, JM; Buck, E; Fox, EM; González-Angulo, AM; Kuba, MG; Liu, S; Manning, HC; Miller, TW; Mills, GB; Sánchez, V; Shyr, Y; Smith, RA; Ye, F	1
Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B	1
Hou, K; Liu, J; Liu, Y; Qu, J; Qu, X; Teng, Y; Xu, L; Zhang, L; Zhang, Y	1
Brundage, RC; Hull, JM; Khatri, A; Kirstein, MN; Williams, BW; Yee, D	1
De Mesmaeker, P; Deleu, I; Dirix, LY; Prové, A; Rasschaert, M; Sas, L; Tjalma, WA; Trinh, XB; Van Dam, PA; Van de Velde, H; Van Laere, SJ; Vermeulen, PB; Vinken, P; Wojtasik, A	1
Masmiquel Comas, L; Nicolau Ramis, J	1
Inazu, M; Itoh, M; Kohno, N; Komatsu, S; Miyazawa, K; Moriya, S; Naito, M; Takase, A; Tomoda, A	1
Gartel, AL; Wang, M	1
Okur, E; Ulukaya, E; Yerlikaya, A	1
Stockler, MR; Wilcken, NR	1
Amerik, AY; Issaenko, OA	1
Chang, KC; Chen, KF; Chu, PY; Liu, CY; Shiau, CW; Tseng, LM	1
Bracke, M; De Wever, O; Emami, S; Gespach, C; Hendrix, A; Hung, MC; Lambein, K; Land, D; Larsen, AK; Ouelaa-Benslama, R; Prévost, G; Sabbah, M	1
Choi, KS; Kim, EH; Kwon, TK; Park, SA; Yoon, MJ	1
Yerlikaya, A	1
Gryczynski, Z; Ranjan, AP; Raut, SL; Thamake, SI; Vishwanatha, JK	1
Cvek, B; Skrott, Z	1
Basile, I; Cathiard, AM; Garcia, M; Gary-Bobo, M; Gleizes, M; Maynadier, M; Sheikh, MS; Shi, J; Vaillant, O; Wah, JL	1
Brunton, VG; Idris, AI; Logan, JG; Marino, S; Muir, M; Sophocleous, A	1
Aoyama, K; Hashimoto, K; Hibino, R; Inazuka, M; Ishikawa, T; Iwai, K; Kosugi, Y; Morimoto, M; Sumi, H; Tozawa, R; Yabuki, M; Yamamoto, S; Yamasaki, H; Yoshida, S; Yoshimatsu, M	1
Bin Sun, H; Fei, X; Hutchins, GD; Lee Stone, K; Liu, X; Martinez, TD; Miller, KD; Mock, BH; Sledge, GW; Wang, JQ; Zheng, QH	1
Dees, EC; Orlowski, RZ	2
Cardoso, F; Durbecq, V; Picart, MJ; Ross, JS; Sotiriou, C	1
Edmund, NA; Moore, DT; Orlowski, RZ; Shi, YY; Small, GW; Somasundaram, S	1
Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL	2
Cooper, C; Liu, GY; Murphy, LC; Niu, YL; Santos, S; Watson, PH	1
Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S	1
Bengston, AL; Denoyelle, C; Esteban, JA; Fernández, Y; Miller, TP; Soengas, MS; Tang, WH	1
Booser, DJ; Broglio, KR; Cristofanilli, M; Esseltine, D; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Krishnamurthy, S; Pusztai, L; Reuben, JM; Stec, J; Yang, CH	1
Albanell, J; Bosch, M; Codony-Servat, J; Domingo-Domenech, J; Gascon, P; Mellado, B; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, MA	1
Doihara, H; Fujita, T; Kawasaki, K; Ogasawara, Y; Shimizu, N; Takabatake, D; Takahashi, H; Tsukuda, K; Washio, K	1
Orlowski, RZ; Shi, YY; Small, GW	1
Alvarez, JV; Frank, DA; Germain, D; Ishii, Y; Keselman, I; Logothetis, D; Mandeli, J; O'Connell, MJ; Pirkmaier, A; Waxman, S	1
Badran, B; Bex, F; Burny, A; Cardoso, F; Desmedt, C; Durbecq, V; Laes, JF; Lagneaux, L; Piccart, M; Ross, JS; Sotiriou, C; Willard-Gallo, K	1
Banwait, S; Benz, CC; Hann, B; Marx, C; Park, JW; Scott, GK; Yau, C; Zhou, Y	1
Jarois, T; Ju, D; Xie, Y; Xu, H	1
Cheng, Y; Shen, P; Zhou, C	1
Hatake, K	1
Badve, S; Bergan, R; Brown, JA; Engel, RH; Gradishar, WJ; O'Regan, RM; Rademaker, A; Von Roenn, JH	1
Nawasreh, M	1
Adler, AS; Chang, HY; Lin, M; Nuyten, DS; Regev, A; Segal, E; van de Vijver, MJ; Wong, DJ	1
Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H	1
Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ	1
Adams, J; Ara, G; Herbst, R; Palombella, VJ; Teicher, BA	1
Benson, AB; Dolan, ME; French, S; Mobarhan, S; Olopade, OI; Rademaker, A; Ratain, MJ; Stucky-Marshall, L	1
Ali, IU; Herbert, BS; Kopelovich, L; Passons, CM; Shay, JW; Wright, AC; Wright, WE	1
Freeman, JW; Gupta, RC; Smith, WA	1

Reviews

6 review(s) available for pyrazines and Breast Cancer

Article	Year
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. British journal of haematology, 2020, Volume: 190, Issue:3 Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides	2020
Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast cancer research : BCR, 2014, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta	2014
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast cancer research : BCR, 2003, Volume: 5, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Clinical Trials as Topic; Cysteine Endopeptidases; Female; Humans; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitins	2003
Targeting the ubiquitin-proteasome pathway in breast cancer. Clinical breast cancer, 2004, Volume: 5, Issue:2 Topics: Animals; Boronic Acids; Bortezomib; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mice; Molecular Biology; Multienzyme Complexes; Neoplasm Transplantation; NF-kappa B; Proteasome Endopeptidase Complex; Protein Transport; Pyrazines; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Ubiquitin	2004
Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future oncology (London, England), 2006, Volume: 2, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Drug Design; Female; Humans; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitin	2006
[Breast cancer and Her-2]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2007

Trials

10 trial(s) available for pyrazines and Breast Cancer

Article	Year
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget, 2014, Nov-15, Volume: 5, Issue:21 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma, Renal Cell; Fatigue; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2014
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome	2008
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors. Anticancer research, 2010, Volume: 30, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines	2010
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clinical breast cancer, 2010, Dec-01, Volume: 10, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Polyethylene Glycols; Pyrazines; Survival Analysis; Treatment Outcome	2010
A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer. Oncology reports, 2012, Volume: 27, Issue:3 Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Boronic Acids; Bortezomib; Breast Neoplasms; Cytokines; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Middle Aged; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tamoxifen	2012
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome	2006
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer investigation, 2007, Volume: 25, Issue:8 Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome	2007
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome	2008
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. British journal of cancer, 2008, May-06, Volume: 98, Issue:9 Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting	2008
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:10 Topics: Anticarcinogenic Agents; Biopsy; Breast Neoplasms; Colonic Polyps; Dose-Response Relationship, Drug; Female; Glutathione; Glutathione Transferase; Hot Temperature; Humans; Lymphocytes; Male; Pyrazines; Rectum; Thiones; Thiophenes; Time Factors	2000

Other Studies

98 other study(ies) available for pyrazines and Breast Cancer

Article	Year
Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7. European journal of medicinal chemistry, 2022, Apr-15, Volume: 234 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Oxazoles; Pentacyclic Triterpenes; Pyrazines; Structure-Activity Relationship; Zebrafish	2022
Design of Novel Imidazopyrazine Derivative against Breast Cancer Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:15 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Imidazoles; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Pyrazines; Receptors, Neuropeptide Y; Structure-Activity Relationship	2023
WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell communication and signaling : CCS, 2019, 08-28, Volume: 17, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Phenotype; Pyrazines; Pyridines; Wnt Proteins; Wnt Signaling Pathway	2019
IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer. International journal of cancer, 2020, 04-15, Volume: 146, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; MAP Kinase Signaling System; MCF-7 Cells; Middle Aged; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyrazines; Receptor, IGF Type 1; Receptors, Estrogen; Tamoxifen	2020
Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors. Cell death & disease, 2020, 02-07, Volume: 11, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 1; Dihydroorotate Dehydrogenase; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; HCT116 Cells; Humans; Leflunomide; MCF-7 Cells; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Oxidoreductases Acting on CH-CH Group Donors; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Ribosomes; Signal Transduction; Tumor Suppressor Protein p53	2020
[Reversal effect of peptide-modified chitosan tetramethylpyrazine nanoparticles on multidrug resistance in tumor cells]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2020, Volume: 45, Issue:22 Topics: Breast Neoplasms; Chitosan; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Nanoparticles; Peptides; Pyrazines	2020
Highly Bright NIR-BRET System for Imaging Molecular Events in Live Cells. Methods in molecular biology (Clifton, N.J.), 2021, Volume: 2274 Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Fluorescence Resonance Energy Transfer; Humans; Imidazoles; Luciferases; Luminescent Agents; Luminescent Measurements; Mice; Mice, Inbred NOD; Mice, SCID; Optical Imaging; Pyrazines; Spectroscopy, Near-Infrared; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells. Cancer science, 2017, Volume: 108, Issue:8 Topics: Autocrine Communication; Axitinib; Breast Neoplasms; Cathepsin G; Cell Aggregation; Female; Humans; Imidazoles; Indazoles; Indoles; Insulin-Like Growth Factor I; MCF-7 Cells; Phosphorylation; Pyrazines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Small Molecule Libraries; Sunitinib	2017
A novel agent attenuates cardiotoxicity and improves antitumor activity of doxorubicin in breast cancer cells. Journal of cellular biochemistry, 2019, Volume: 120, Issue:4 Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Doxorubicin; Endoplasmic Reticulum Stress; Humans; Lactates; Oxidative Stress; Pyrazines; Rats; Signal Transduction; Zebrafish	2019
Highly bright and stable NIR-BRET with blue-shifted coelenterazine derivatives for deep-tissue imaging of molecular events Theranostics, 2019, Volume: 9, Issue:9 Topics: Amino Acid Sequence; Animals; Binding Sites; Breast Neoplasms; Chlorocebus aethiops; COS Cells; Female; Fluorescence Resonance Energy Transfer; HeLa Cells; Heterografts; Humans; Imidazoles; Liver Neoplasms; Luciferases; Luminescent Agents; Luminescent Measurements; Luminescent Proteins; Lung Neoplasms; Mice; Models, Molecular; Molecular Imaging; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Pyrazines; Receptors, Estrogen; Recombinant Fusion Proteins; Red Fluorescent Protein; Single-Cell Analysis	2019
ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. Cell death & disease, 2019, 06-12, Volume: 10, Issue:6 Topics: A549 Cells; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Autophagy; Breast Neoplasms; Cell Culture Techniques; Cellular Microenvironment; Cellular Senescence; Checkpoint Kinase 1; Cisplatin; DNA Damage; DNA Replication; DNA-Binding Proteins; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Female; Histones; Humans; MCF-7 Cells; Pyrazines; S Phase Cell Cycle Checkpoints; Sulfones; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2019
Development of a quantitative method to measure EV uptake. Scientific reports, 2019, 07-19, Volume: 9, Issue:1 Topics: Biological Transport; Breast Neoplasms; Cell Line, Tumor; Extracellular Vesicles; Female; Genes, Reporter; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Imidazoles; Luciferases, Renilla; Luminescent Measurements; Nanoparticles; Pyrazines; Recombinant Fusion Proteins; Sensitivity and Specificity; Subcellular Fractions; Tetraspanin 29; Tetraspanin 30	2019
Tandem multicomponent reactions toward the design and synthesis of novel antibacterial and cytotoxic motifs. Current medicinal chemistry, 2013, Volume: 20, Issue:11 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Imidazoles; Melanoma; Pyrazines; Pyridines	2013
Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells. Molecular medicine reports, 2013, Volume: 8, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Pyrazines	2013
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. Biochemical and biophysical research communications, 2013, Jul-19, Volume: 437, Issue:1 Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Clarithromycin; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Inclusion Bodies; Intracellular Space; Mice; Proteolysis; Pyrazines; Transcription Factor CHOP; Vorinostat	2013
Anticancer agent ukrain and bortezomib combination is synergistic in 4T1 breast cancer cells. Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Berberine Alkaloids; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Melanoma, Experimental; Phenanthridines; Pyrazines	2014
Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists. Bioorganic & medicinal chemistry, 2013, Sep-15, Volume: 21, Issue:18 Topics: Animals; Benzopyrans; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Female; Half-Life; Humans; Inhibitor of Apoptosis Proteins; Mice; Molecular Dynamics Simulation; Protein Structure, Tertiary; Pyrazines; Pyrroles; RNA, Messenger; Stereoisomerism; Transplantation, Heterologous; Tumor Necrosis Factor-alpha	2013
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:10 Topics: Acetophenones; Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Glucose; Humans; MCF-7 Cells; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase C-delta; Pyrazines; Ubiquitin	2013
TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. International journal of oncology, 2014, Volume: 44, Issue:2 Topics: Anthracyclines; Antineoplastic Agents; Apoptosis; ATPases Associated with Diverse Cellular Activities; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2014
Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas. Bulletin of experimental biology and medicine, 2013, Volume: 156, Issue:2 Topics: Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Chymotrypsin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Proteasome Endopeptidase Complex; Pyrazines; Thyroid Gland; Thyroid Neoplasms	2013
NanoLuc reporter for dual luciferase imaging in living animals. Molecular imaging, 2013, Volume: 12, Issue:7 Topics: Animals; Breast Neoplasms; Cell Line; Disease Progression; Female; Heterografts; Imidazoles; Luciferases; Luciferases, Firefly; Luminescent Measurements; Mice; Molecular Imaging; Neoplasm Transplantation; Pyrazines; Signal Transduction; Substrate Specificity; Transfection; Transforming Growth Factor beta	2013
Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231. Molecular and cellular biochemistry, 2014, Volume: 389, Issue:1-2 Topics: Antineoplastic Agents; Apoptosis; beta-Galactosidase; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Female; Fibroblasts; HSP70 Heat-Shock Proteins; Humans; Hypoxia; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2014
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. International journal of oncology, 2014, Volume: 44, Issue:4 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Kinase; I-kappa B Proteins; Imidazoles; MCF-7 Cells; NF-KappaB Inhibitor alpha; Phosphorylation; Pyrazines; Quinoxalines; Transcription Factor RelA	2014
DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo. The Journal of pharmacy and pharmacology, 2014, Volume: 66, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Herb-Drug Interactions; Humans; Ligusticum; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Phytotherapy; Plant Extracts; Pyrazines	2014
Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis. Drug discoveries & therapeutics, 2014, Volume: 8, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Mitochondria; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction	2014
Cytotoxic activity of octahydropyrazin[2,1-a:5,4-a']diisoquinoline derivatives in human breast cancer cells. Archives of pharmacal research, 2015, Volume: 38, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Cytotoxins; Dose-Response Relationship, Drug; Female; Humans; Isoquinolines; MCF-7 Cells; Membrane Potential, Mitochondrial; Pyrazines	2015
A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. Journal of proteomics, 2015, Jan-15, Volume: 113 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; DNA Replication; DNA, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Energy Metabolism; Female; Humans; Proteasome Endopeptidase Complex; Protein Folding; Protein Processing, Post-Translational; Proteome; Proteomics; Pyrazines; Tumor Suppressor Protein p53	2015
Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells. Cell death & disease, 2014, Nov-27, Volume: 5 Topics: Aurovertins; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cyclin D3; eIF-2 Kinase; Electron Transport; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Female; Humans; Mitochondrial Proton-Translocating ATPases; Molecular Targeted Therapy; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, Purinergic; Tumor Stem Cell Assay; Ubiquitin; Unfolded Protein Response; Vacuoles	2014
Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy. Journal of vascular and interventional radiology : JVIR, 2014, Volume: 25, Issue:12 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Catheter Ablation; Chemotherapy, Adjuvant; Disease Models, Animal; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Liposomes; Liver; Pyrazines; Rats; Rats, Inbred F344; Up-Regulation	2014
Suppression of BRCA1 sensitizes cells to proteasome inhibitors. Cell death & disease, 2014, Dec-18, Volume: 5 Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Down-Regulation; Female; Gene Silencing; Humans; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Retinoblastoma Protein; RNA, Small Interfering; Signal Transduction	2014
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. International journal of cancer, 2015, Aug-01, Volume: 137, Issue:3 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Prognosis; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2015
MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Molecular cell, 2015, Jul-16, Volume: 59, Issue:2 Topics: 3' Untranslated Regions; Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor Proteins; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; HCT116 Cells; Hep G2 Cells; Humans; MCF-7 Cells; Mice; MicroRNAs; Molecular Chaperones; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Tumor Suppressor Protein p53	2015
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Molecular oncology, 2016, Volume: 10, Issue:2 Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Checkpoint Kinase 1; Cohort Studies; DNA Repair; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Humans; Indoles; MCF-7 Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Phosphorylation; Protein Kinases; Pyrazines; Pyridones; Radiation Tolerance; RNA Interference; RNA, Small Interfering; Serine; Sulfones; Up-Regulation	2016
Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer. Cancer letters, 2016, 07-10, Volume: 377, Issue:1 Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Imidazoles; Insulin-Like Growth Factor I; MCF-7 Cells; Mucoproteins; Oncogene Proteins; Protein Binding; Proteins; Proteolysis; Pyrazines; RNA Interference; Signal Transduction; Time Factors; Transfection	2016
A novel agent exerts antitumor activity in breast cancer cells by targeting mitochondrial complex II. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cell Respiration; Dose-Response Relationship, Drug; Electron Transport Complex II; Energy Metabolism; Enzyme Inhibitors; Female; Humans; Lactates; MCF-7 Cells; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mitochondria; Pyrazines; Reactive Oxygen Species; Signal Transduction; Time Factors; Tumor Burden	2016
Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress. Oncotarget, 2016, Jun-07, Volume: 7, Issue:23 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; DNA Repair; Homologous Recombination; Humans; MCF-7 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes; Urea	2016
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin. Oncotarget, 2016, 08-30, Volume: 7, Issue:35 Topics: Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Breast Neoplasms; Cell Survival; Cisplatin; DNA Damage; Histones; Humans; Imidazoles; Inhibitory Concentration 50; MCF-7 Cells; Oncogenes; Phosphorylation; Pyrazines; Pyrazoles; Receptor, IGF Type 1; Receptors, Somatomedin; Recombinant Proteins; RNA, Small Interfering; Triazines	2016
Two-Photon Tracer for Human Epidermal Growth Factor Receptor-2: Detection of Breast Cancer in a Live Tissue. Analytical chemistry, 2016, 10-04, Volume: 88, Issue:19 Topics: Animals; Benzofurans; Breast Neoplasms; Cell Line, Tumor; Fluorescent Dyes; Humans; Light; Mice, Inbred BALB C; Pyrazines; Receptor, ErbB-2; Recombinant Fusion Proteins	2016
Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity. European journal of medicinal chemistry, 2017, Jan-27, Volume: 126 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Female; Humans; Mice; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2017
Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. International journal of molecular medicine, 2008, Volume: 22, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Inhibitory Concentration 50; Melanoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53	2008
New evidence in oncologic and cardiocirculatory medicine. Internal and emergency medicine, 2009, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines	2009
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clinical and experimental immunology, 2009, Volume: 155, Issue:3 Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Female; Humans; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, SCID; Protease Inhibitors; Pyrazines; Receptors, Death Domain; RNA, Messenger; Xenograft Model Antitumor Assays	2009
Combination effects of SC144 and cytotoxic anticancer agents. Anti-cancer drugs, 2009, Volume: 20, Issue:5 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytotoxins; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Pyrazines; Quinoxalines; Xenograft Model Antitumor Assays	2009
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer research, 2009, May-15, Volume: 69, Issue:10 Topics: Activating Transcription Factor 4; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Division; Cell Line, Tumor; Female; Flow Cytometry; Humans; Immunohistochemistry; Neoplasm Proteins; Polymerase Chain Reaction; Pyrazines; RNA, Neoplasm; RNA, Small Interfering	2009
Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7. BioTechniques, 2009, Volume: 47, Issue:1 Topics: Animals; Biological Assay; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chemokine CXCL12; Copepoda; Drug Discovery; Female; Genetic Vectors; Green Fluorescent Proteins; Humans; Imidazoles; Kidney; Lentivirus; Luciferases; Luminescent Measurements; Luminescent Proteins; Promoter Regions, Genetic; Protein Binding; Pyrazines; Receptors, CXCR; Receptors, CXCR4; Recombinant Fusion Proteins; Signal Transduction; Substrate Specificity; Transduction, Genetic	2009
BU-32: a novel proteasome inhibitor for breast cancer. Breast cancer research : BCR, 2009, Volume: 11, Issue:5 Topics: Animals; Apoptosis; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chymotrypsin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrazoles; Xenograft Model Antitumor Assays	2009
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Dec-01, Volume: 15, Issue:23 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53	2009
Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene, 2010, Mar-11, Volume: 29, Issue:10 Topics: Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Chymotrypsin; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Promoter Regions, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Polymerase II; Signal Transduction	2010
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Female; Flow Cytometry; Humans; Mesothelioma; Pilot Projects; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Time Factors	2010
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy, 2010, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Caspases; Cathepsins; Cell Death; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Estrogen Receptor Modulators; Female; Humans; Metabolism; Pyrazines; Receptors, Estrogen; Signal Transduction; Stress, Physiological; Tumor Cells, Cultured	2010
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer research, 2010, May-01, Volume: 70, Issue:9 Topics: Benzoquinones; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Clathrin; Down-Regulation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lysosomes; Mass Spectrometry; Microscopy, Fluorescence; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, ErbB-2; Ubiquitination	2010
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. Cancer science, 2010, Volume: 101, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2	2010
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Osteolysis; Positron-Emission Tomography; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Xenograft Model Antitumor Assays	2010
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fluorescent Antibody Technique; Fulvestrant; Green Fluorescent Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazines; Receptors, Estrogen; Tamoxifen; Tumor Burden; Unfolded Protein Response; Xenograft Model Antitumor Assays	2011
Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells. Molecular cancer research : MCR, 2011, Volume: 9, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azocines; Benzhydryl Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Caspases; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, bcl-2; Gossypol; Humans; Mice; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured	2011
Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Adenosine Triphosphatases; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Pyrazines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vasodilator Agents	2012
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast cancer research and treatment, 2012, Volume: 133, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays	2012
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 Topics: Adaptor Proteins, Signal Transducing; Animals; Aurora Kinases; Breast Neoplasms; Computer Simulation; Dasatinib; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Inhibitory Concentration 50; Melanocytes; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Oncogenes; Phenotype; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrazines; Pyrimidines; RNA-Binding Proteins; Structure-Activity Relationship; Thiazoles	2011
Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer research, 2011, Sep-01, Volume: 71, Issue:17 Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Neoplasms, Hormone-Dependent; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription, Genetic; Ubiquitination	2011
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer research, 2011, Nov-01, Volume: 71, Issue:21 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Protein-Tyrosine Kinases; Pyrazines; Random Allocation; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; RNA Interference; Signal Transduction; Tamoxifen; Xenograft Model Antitumor Assays	2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature medicine, 2011, Nov-06, Volume: 17, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Breast Neoplasms; Carboxypeptidases; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Multiple Myeloma; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination	2011
Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration. Molecular medicine reports, 2012, Volume: 5, Issue:2 Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Female; Humans; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Up-Regulation	2012
Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine. The AAPS journal, 2012, Volume: 14, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Models, Biological; Pyrazines; Receptor, IGF Type 1; Signal Transduction; Somatomedins	2012
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1 Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms	2012
Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. International journal of oncology, 2012, Volume: 40, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Clarithromycin; Cytotoxicity, Immunologic; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression; Humans; Pyrazines; Transcription Factor CHOP	2012
Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton. Cancer biology & therapy, 2012, Feb-01, Volume: 13, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Male; Mice; Mice, Nude; Nanocapsules; Proteasome Endopeptidase Complex; Pyrazines; Random Allocation; Thiostrepton; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays	2012
The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrazines; Tumor Suppressor Protein p53	2012
Why is management of cancer pain still a problem? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-01, Volume: 30, Issue:16 Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines	2012
Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell cycle (Georgetown, Tex.), 2012, 05-01, Volume: 11, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Boronic Acids; Bortezomib; Breast Neoplasms; Catalytic Domain; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Chalcone; Cyclin D1; Cysteine; Dose-Response Relationship, Drug; Endopeptidases; Female; HeLa Cells; Humans; Ovarian Neoplasms; Phenotype; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitins	2012
CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast cancer research : BCR, 2012, Apr-26, Volume: 14, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptors, Estrogen; Xenograft Model Antitumor Assays	2012
Identification of a GαGβγ, AKT and PKCα signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition. International journal of oncology, 2012, Volume: 41, Issue:1 Topics: Biomarkers, Tumor; Breast Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclohexanes; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Gene Knockdown Techniques; Heterotrimeric GTP-Binding Proteins; Humans; Mitogen-Activated Protein Kinases; Pertussis Toxin; Phenotype; Prognosis; Protein Kinase C-alpha; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Repressor Proteins; RNA Interference; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Xanthenes	2012
Simultaneous mitochondrial Ca(2+) overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells. Cancer letters, 2012, Nov-28, Volume: 324, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Cell Death; Cell Line, Tumor; Clonazepam; Curcumin; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Female; Humans; Mitochondria; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sodium-Calcium Exchanger; Thiazepines; Time Factors	2012
Expression of heme oxygenase-1 in response to proteasomal inhibition. Protein and peptide letters, 2012, Volume: 19, Issue:12 Topics: Animals; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Induction; Female; Genes, p53; Heme Oxygenase-1; Humans; Leupeptins; Melanoma, Experimental; Mice; Molecular Sequence Data; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Regulatory Sequences, Nucleic Acid	2012
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials, 2012, Volume: 33, Issue:29 Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Curcumin; Drug Carriers; Female; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Osteoporosis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines	2012
Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Mini reviews in medicinal chemistry, 2012, Volume: 12, Issue:12 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Coordination Complexes; Copper; Ditiocarb; Humans; Oxidative Stress; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines	2012
Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells. Molecular cancer research : MCR, 2012, Volume: 10, Issue:11 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Estrogen Receptor alpha; Female; HCT116 Cells; Humans; MCF-7 Cells; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2012
Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:5 Topics: Animals; Bone Remodeling; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Imidazoles; Mice; Osteoclasts; Osteolysis; Protein-Tyrosine Kinases; Pyrazines; Receptor, IGF Type 1	2013
Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins. Molecular cancer therapeutics, 2013, Volume: 12, Issue:2 Topics: Animals; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Caspases; Cell Line; Cell Survival; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Oligopeptides; Pyrazines; Signal Transduction; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors	2013
Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nuclear medicine and biology, 2002, Volume: 29, Issue:7 Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carbon Radioisotopes; Humans; Hydroxamic Acids; Metalloendopeptidases; Protease Inhibitors; Pyrazines; Radiopharmaceuticals; Sulfonamides; Tomography, Emission-Computed	2002
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Molecular pharmacology, 2004, Volume: 66, Issue:6 Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Breast; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Dual Specificity Phosphatase 1; Fibroblasts; Genes, myc; Humans; Immediate-Early Proteins; Mice; Mice, Knockout; Mice, Nude; Phosphoprotein Phosphatases; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Pyrazines; Recombinant Proteins; Transplantation, Heterologous	2004
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. Annals of clinical and laboratory science, 2004,Summer, Volume: 34, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Pamidronate; Piperazines; Pyrazines; Pyrimidines; ras Proteins; Sirolimus	2004
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Antigens, Neoplasm; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Intraductal, Noninfiltrating; Cell Hypoxia; Cell Survival; Down-Regulation; Estrogen Receptor alpha; Female; Glucose Transporter Type 1; Humans; Immunoenzyme Techniques; Monosaccharide Transport Proteins; Neoplasm Invasiveness; Oxygen; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured	2004
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:1 Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured	2005
Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-kappaB and p53 in breast cancer cell lines. Annals of clinical and laboratory science, 2005,Winter, Volume: 35, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Division; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Phosphorylation; Protease Inhibitors; Proteome; Pyrazines; Tumor Suppressor Protein p53	2005
Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. The Journal of biological chemistry, 2006, Jan-13, Volume: 281, Issue:2 Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Binding, Competitive; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Death; Cell Line; Cell Line, Tumor; Cell Survival; Drug Antagonism; Fibroblasts; Free Radicals; Humans; Immunoblotting; Kinetics; Leupeptins; Melanocytes; Melanoma; Membrane Potentials; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Skin; Time Factors	2006
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Molecular cancer therapeutics, 2006, Volume: 5, Issue:3 Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Enzyme Activation; ErbB Receptors; Female; Humans; Immediate-Early Proteins; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 1; Phosphoprotein Phosphatases; Phosphorylation; Proteasome Inhibitors; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2	2006
Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anti-cancer drugs, 2006, Volume: 17, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Drug Resistance; Drug Resistance, Neoplasm; Female; Humans; Protease Inhibitors; Proteasome Inhibitors; PTEN Phosphohydrolase; Pyrazines; Trastuzumab	2006
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast cancer research and treatment, 2006, Volume: 100, Issue:1 Topics: Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Transformed; Cell Line, Tumor; Dual Specificity Phosphatase 1; Female; Humans; Immediate-Early Proteins; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Protease Inhibitors; Protein Phosphatase 1; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Pyrazines	2006
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. Journal of the National Cancer Institute, 2006, Sep-06, Volume: 98, Issue:17 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Biomarkers, Tumor; Boronic Acids; Bortezomib; Breast Neoplasms; Calcium; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Microarray Analysis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; STAT3 Transcription Factor; Transplantation, Heterologous; Up-Regulation	2006
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Molecular cancer therapeutics, 2006, Volume: 5, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Humans; NF-kappa B; Pyrazines; Receptor, ErbB-2; Trastuzumab	2006
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Molecular pharmacology, 2007, Volume: 71, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Drug Therapy, Combination; Humans; Oxidation-Reduction; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptor, ErbB-2; Receptors, Estrogen; Transcription, Genetic	2007
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells. Breast cancer research and treatment, 2008, Volume: 107, Issue:2 Topics: Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feedback, Physiological; Humans; Leupeptins; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Temperature; Tetrazolium Salts; Thiazoles	2008
Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochimica et biophysica acta, 2007, Volume: 1770, Issue:7 Topics: Antibiotics, Antineoplastic; Biological Transport; Breast Neoplasms; Calcium Channel Blockers; Cell Line, Tumor; Diffusion; Doxorubicin; Drug Resistance, Multiple; Female; Humans; Kinetics; Microelectrodes; Models, Biological; Pyrazines; Verapamil	2007
Chemo-, regio-, and stereoselectivity of F-ring opening reactions in the cephalostatin series. Bioorganic & medicinal chemistry, 2008, Jan-01, Volume: 16, Issue:1 Topics: Antineoplastic Agents; Boranes; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Phenazines; Pyrazines; Spiro Compounds; Steroids; Stomach Neoplasms; Structure-Activity Relationship	2008
Revealing targeted therapy for human cancer by gene module maps. Cancer research, 2008, Jan-15, Volume: 68, Issue:2 Topics: Algorithms; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Chromosome Mapping; Electronic Data Processing; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Targeting; Genes, Mitochondrial; Genetic Therapy; Humans; Neoplasm Invasiveness; Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Wounds and Injuries	2008
The proteasome inhibitor PS-341 in cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dipeptides; Drug Synergism; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Ubiquitins	1999
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Disease Progression; DNA, Complementary; Eflornithine; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Li-Fraumeni Syndrome; Oligodeoxyribonucleotides, Antisense; Point Mutation; Pyrazines; Reverse Transcriptase Inhibitors; Tamoxifen; Telomerase; Thiones; Thiophenes; Transformation, Genetic; Tretinoin	2001
Effect of chemopreventive agents on DNA adduction induced by the potent mammary carcinogen dibenzo[a,l]pyrene in the human breast cells MCF-7. Mutation research, 2001, Sep-01, Volume: 480-481 Topics: Anticarcinogenic Agents; Antimutagenic Agents; Antineoplastic Agents; Benzopyrenes; Breast; Breast Neoplasms; Carcinogens; Cell Line; Chemoprevention; Chlorophyllides; DNA Adducts; Dose-Response Relationship, Drug; Female; Humans; Pyrazines; Thiones; Thiophenes	2001